- Adjunct Professor, Global Health
- Professor, Medicine - Allergy and Infectious Dis.
- Adjunct Professor, Laboratory Medicine and Pathology
- Director, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N
E5-113
Box 19024
United States
Select from the following:
Dr. Julie McElrath has witnessed the devastation of the HIV epidemic since the early 1980s as an infectious disease physician caring for patients and as a clinical researcher overseeing international collaborative cohort and vaccine studies that may inform and accelerate HIV vaccine development. She is the Principal Investigator of the HIV Vaccine Trials Network (HVTN) Laboratory Program and the Seattle HIV Vaccine Trials Unit, and has led several projects within the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD).
For more information on Dr. McElrath, click here.
- MD (Medical University of South Carolina)
- PhD (Medical University of South Carolina)
- BS (Furman University)
- HIV/AIDS
- Infectious Diseases
- TB
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, Sutherland L, Mildenberg B, Morton G, Yates NL, Mize GJ, Pollara J, Hladik F, Ochsenbauer C, Denny TN, Warrier R, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Kaewkungwal J, Ferrari G, Shaw GM, Xia SM, Liao HX, Montefiori DC, Tomaras GD, Haynes BF, McElrath JM.
EBioMedicine. 2016 Dec;14:97-111. doi: 10.1016/j.ebiom.2016.11.024. Epub 2016 Nov 21.
PMID: 27919754 Free PMC Article
Vaccination establishes clonal relatives of germinal center T cells in the blood of humans.
Heit A, Schmitz F, Gerdts S, Flach B, Moore MS, Perkins JA, Robins HS, Aderem A, Spearman P, Tomaras GD, De Rosa SC, McElrath MJ.
J Exp Med. 2017 Jul 3;214(7):2139-2152. doi: 10.1084/jem.20161794. Epub 2017 Jun 21.
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.
J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086